MimiVax

MimiVax is a clinical-stage biotechnology company focused on immunotherapy research and the clinical translation of new drugs for cancer treatment. It was established to develop and commercialize its lead candidate drug, SurVaxM, a patented immunotherapy targeting the cell survival protein survivin. SurVaxM is administered via subcutaneous injection, stimulating the patient's own immune response to control tumor growth and prevent future disease recurrence.